{
    "clinical_study": {
        "@rank": "4861", 
        "arm_group": [
            {
                "arm_group_label": "Impracor (Ketoprofen 10% Cream)", 
                "arm_group_type": "Experimental", 
                "description": "Topical Cream over a period of 14 days"
            }, 
            {
                "arm_group_label": "Placebo Cream:", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Topical Cream over a period of 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to assess analgesic efficacy  of Impracor (Ketoprofen\n      10% Cream) compared to placebo for acute pain associated with OA flare of the knee."
        }, 
        "brief_title": "Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee", 
        "condition": "Acute Pain (Flare) Associated With Osteoarthritis (OA) of the Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of OA of the knee according to the ACR criteria.\n\n          -  Kellgren-Lawrence grade 2-3 disease\n\n          -  Be willing to stop taking all analgesics including NSAIDs and opioids for the\n             duration of the study, with exception of study-specified rescue medication.\n\n        Exclusion Criteria:\n\n          -  Total knee replacement surgery tentatively scheduled within next 6 months.\n\n          -  Palpable knee effusion.\n\n          -  Significant pain outside the target knee, including significant hip, back, or\n             contralateral knee pain.\n\n          -  Any type of orthopedic and/or prosthetic device or any skin abnormalities on the\n             target knee that would prevent evaluations of local tolerability.\n\n          -  History of asthma, rheumatoid arthritis, chronic inflammatory disease (e.g.,\n             colitis), or fibromyalgia.\n\n          -  History of gastrointestinal bleeding or peptic ulcer disease within the past 3 years.\n\n          -  Have a positive urine drug test for illegal drug substances, non-prescribed\n             controlled substances, or alcohol at screening.\n\n          -  Acute or chronic illness that in the opinion of the investigator could compromise the\n             integrity of study data or place the subject at risk by participating in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890902", 
            "org_study_id": "IPI-110-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Impracor (Ketoprofen 10% Cream)", 
                "intervention_name": "Ketoprofen 10% Cream", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Impracor", 
                    "IPI-110"
                ]
            }, 
            {
                "arm_group_label": "Placebo Cream:", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketoprofen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 8, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Multicenter, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary endpoint will be measured by changes in WOMAC pain subscale scores calculated by comparing baseline WOMAC pain subscale scores on Day 1 to the average WOMAC Pain Subscale scores on Day 4, 6, and 8.", 
            "safety_issue": "No", 
            "time_frame": "Day 4, 6 and 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890902"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in Patient Global Assessment of knee arthritis using the modified Patient Overall Health Assessment from Day 1 to Day 8.", 
            "safety_issue": "No", 
            "time_frame": "Day 8"
        }, 
        "source": "Imprimis Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Imprimis Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}